Stopping CBD – Can You Quit Cold Turkey? CBD is great for many people for several reasons. After having an excellent experience with CBD, various situations may occur that might have you In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.
Stopping CBD – Can You Quit Cold Turkey?
CBD is great for many people for several reasons. After having an excellent experience with CBD, various situations may occur that might have you considering taking a break from your daily CBD routine. And you want to find the best way to have the smoothest experience with stopping CBD.
Stopping CBD cold turkey won’t have withdrawal symptoms. CBD is reported safe & non-addictive to avid users. After a few days of stopping, old symptoms may begin cropping up again. Before stopping CBD, talk to your doctor to verify it’s safe without impacting any other medications you’re taking.
Below, we’ll look at stories of those who’ve quit CBD cold turkey, as well as highlight research surrounding quitting CBD.
Can You Quit CBD Cold Turkey?
Below, we highlight John’s “poor” experience in quitting CBD cold turkey.
While you can quit CBD cold turkey without it causing any significant extra trouble, John doesn’t recommend stopping CBD all at once.
If you’re taking CBD with other medications, quitting CBD cold turkey can impact how your other medications interact with your body and may cause issues.
Before you quit CBD cold turkey, it’s best to have a quick chat with your primary healthcare provider.
Do You Need To Wean Off CBD Oil?
As a general rule, you don’t need to wean off of CBD, however, if you want a more comfortable experience in stopping CBD — it’s best to slowly taper off.
Slowly weaning yourself off of CBD can make returning to normal aches and pains a bit less shocking on the system.
Instead of having your issues come back all at once, it can be a more gentle experience if you slowly decrease your CBD intake until you can completely stop.
Users quitting CBD generally report the process of stopping CBD to be mild and subtle that doesn’t last for long periods of time.
Does CBD Have Withdrawal Symptoms?
In total, CBD doesn’t have any specific withdrawal symptoms (in itself), according to those who were able to completely stop CBD.
After taking CBD for several months, your body starts entering into a more optimal state of balance and homeostasis regulation throughout nearly every cell and system within your body.
When you’re body is in an optimal state of homeostasis from CBD providing nutrients to the Endocannabinoid System (ECS), your body and mind are experiencing this state as normal and adapt to it.
Stopping CBD, when your body expects it as part of its normal routine, may cause you to experience a resurgence of symptoms from issues CBD was aiding.
You won’t experience any new withdrawal symptoms from stopping CBD, however, you may find your old symptoms popping back up into your new normal daily routine that doesn’t involve CBD.
Side Effects Of Abruptly Stopping CBD Oil
A personal story of John Kaste quitting CBD — cold turkey — for ten days in extensive detail.
In short, John measured four areas including pain, sleep quality, injury recovery, and overall mood.
- Daily aches and pains more through his normal range of motion.
- Less flexibility
- Loss of sleep quality
- Slower to recover from physical activities
- More stress
- More emotional
- More annoyed, angry, and frustrated
Other users who’ve stopped taking CBD reported feeling a bit more anxious and weren’t sleeping as well as they were when taking CBD regularly.
Any benefit you received from taking CBD will cease and old symptoms can crop up as your body finished removing the remaining CBD from its system.
How Long Does It Take To Detox From CBD?
According to Healthline, CBD can remain in your body for as little as two days and up to five days — more or less.
Each user will process CBD differently and some can have CBD remain in their system for several weeks.
What determines how long CBD stays in your systems involves.
- Dosage – How much
- How often you take CBD throughout the day
- Method of consumption
- Your body chemistry
- Your diet can affect how quickly CBD is metabolized by your body
With numerous types of CBD products on the market with a wide range of strengths, it can be hard to pinpoint how long specifically a CBD detox will take.
Is CBD Addictive?
According to Dr. Jeffrey Chen, MD, CBD is not addictive, with the World Health Organization (WHO) confirming CBD doesn’t have abuse or dependence potential.
Published in the Journal of Cannabis & Cannabinoid Research, reports CBD is non-hedonic, meaning CBD doesn’t give you pleasure.
Further evidence shows CBD can actually reduce drug-seeking behavior.
The journal of Substance Abuse: Research & Treatment shows how CBD can modulate certain circuits in the brain involving drug addiction.
Comprehensive results from 100+ studies verify the safety profile and tolerability of large chronic doses of CBD in humans.
Is CBD Addictive For Dogs?
CBD is not addictive for dogs and is safe for your dog to take every day, as needed.
If your dog is taking any other medications, it’s best to talk with a qualified veterinarian to verify taking CBD is the best course of action.
Dr. Casara Andre, the founder of Veterinary Cannabis Education & Consulting, tells The Washington Post that there’s no risk of addiction with taking CBD.
Should I Stop Taking CBD Before Surgery?
According to Kirby Plastic Surgery, you should stop taking CBD two weeks before your surgery.
CBD can have the potential to interfere with anesthesia, reacting with certain liver enzymes.
Abrupt withdrawal of cannabidiol (CBD): A randomized trial
Rationale: The rationale of this study was to assess occurrence of withdrawal symptoms induced by abrupt cessation of cannabidiol (CBD) after prolonged administration in healthy volunteers.
Methods: Thirty volunteers were randomized to receive 750 mg of a plant-derived pharmaceutical formulation of highly purified CBD in oral solution (100 mg/mL; Epidiolex® in the United States and Epidyolex® in Europe) twice daily (b.i.d.) for 4 weeks (Part 1) followed by 2 weeks of 750 mg b.i.d. CBD (Part 2, Arm 1) or matched placebo (Part 2, Arm 2). All volunteers completed the Cannabis Withdrawal Scale (CWS) and the 20-item Penn Physician Withdrawal Checklist (PWC-20) on days -1, 21, 28, 31, 35, 42, and at follow-up.
Results: Median CWS and PWC-20 scores slightly decreased from Part 1 to Part 2. Median CWS scores ranged from 0.0 to 4.0 (out of a possible 190) in Arm 1 and 0.0 to 0.5 in Arm 2. Median PWC-20 scores were 0.0 (out of a possible 60) in both arms. Twenty-nine (97%) volunteers in Part 1 reported all-causality treatment-emergent adverse events (AEs); the most commonly reported was diarrhea (63%). In Part 2, Arm 1, 6 (67%) volunteers reported all-causality AEs; the most commonly reported was diarrhea (44%). In Part 2, Arm 2, 9 (75%) volunteers reported all-causality AEs; the most commonly reported was headache (58%). Nine volunteers withdrew because of AEs in Part 1; 1 withdrew in Part 2, Arm 2, because of an AE that began in Part 1. Four severe AEs were reported in Part 1; the remainder were mild or moderate. No serious AEs were reported.
Conclusion: In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.
Keywords: Cannabidiol; Cannabinoid; Drug withdrawal; Epilepsy; Seizure.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest All authors met the International Committee of Medical Journal Editors authorship criteria. Neither honoraria nor payments were made for authorship. Lesley Taylor was an employee of GW Research Ltd. at the time the work was completed. Julie Crockett is an employee of GW Research Ltd. and has share options in the company. Bola Tayo is an employee of GW Research Ltd. and owns shares in the company. Daniel Checketts is an employee of GW Research Ltd. Kenneth Sommerville was an employee of Greenwich Biosciences, Inc. at the time the work was completed.
Perry MS. Perry MS. Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671. Epilepsy Curr. 2019. PMID: 30955420 Free PMC article.
Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M. Ben-Menachem E, et al. CNS Drugs. 2020 Jun;34(6):661-672. doi: 10.1007/s40263-020-00726-4. CNS Drugs. 2020. PMID: 32350749 Free PMC article. Clinical Trial.
Perkins D, Butler J, Ong K, Nguyen TH, Cox S, Francis B, Mcintosh M, Lilley B. Perkins D, et al. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):575-586. doi: 10.1007/s13318-020-00624-6. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32409982 Free PMC article. Clinical Trial.
Franco V, Perucca E. Franco V, et al. Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4. Drugs. 2019. PMID: 31372958 Review.
Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK. Martin-Santos R, et al. Curr Pharm Des. 2012;18(32):4966-79. doi: 10.2174/138161212802884780. Curr Pharm Des. 2012. PMID: 22716148 Review.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, Trezza V, van Loveren H, Albert O, Dumas C, Germini A, Gelbmann W, Kass G, Kouloura E, Noriega Fernandez E, Rossi A, Knutsen HK. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al. EFSA J. 2022 Jun 7;20(6):e07322. doi: 10.2903/j.efsa.2022.7322. eCollection 2022 Jun. EFSA J. 2022. PMID: 35686177 Free PMC article.
Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. Kirkland AE, et al. Psychiatry Res. 2022 Feb;308:114347. doi: 10.1016/j.psychres.2021.114347. Epub 2021 Dec 20. Psychiatry Res. 2022. PMID: 34952255 Review.
Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Connor JP, et al. Addiction. 2022 Jul;117(7):2075-2095. doi: 10.1111/add.15743. Epub 2022 Jan 10. Addiction. 2022. PMID: 34791767 Free PMC article. Review.
Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, Vandrey R. Martin EL, et al. Front Psychiatry. 2021 Sep 9;12:729800. doi: 10.3389/fpsyt.2021.729800. eCollection 2021. Front Psychiatry. 2021. PMID: 34566726 Free PMC article.
Morel A, Lebard P, Dereux A, Azuar J, Questel F, Bellivier F, Marie-Claire C, Fatséas M, Vorspan F, Bloch V. Morel A, et al. Front Psychiatry. 2021 Feb 22;12:565617. doi: 10.3389/fpsyt.2021.565617. eCollection 2021. Front Psychiatry. 2021. PMID: 33692705 Free PMC article. Review.